Bio-Techne Corp Reports Q2 Revenue of $295.9M

By Chris Stiles • Wednesday, February 04 12:05 • Permanent Link

Bio-Techne Corporation (NASDAQ: TECH) has released its financial results for the second quarter ending December 31, 2025. The company reported second quarter revenue of $295.9 million, with reported and organic growth remaining flat compared to the prior year. However, foreign currency exchange had a favorable impact of 2%, while non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2%.

In terms of earnings per share (EPS), the company reported a GAAP EPS of $0.24 versus $0.22 one year ago. Additionally, Bio-Techne delivered adjusted EPS of $0.46 compared to $0.42 one year ago. The ongoing productivity and cost containment initiatives led to a 31.1% adjusted operating margin, representing an increase of 100 basis points compared to the prior year period.

The company's management highlighted that strong commercial execution and improving end-markets drove growth in the China/APAC region for the third consecutive quarter. The protein sciences segment's net sales were $215.1 million, reflecting an increase of 2% from the second quarter of fiscal 2025, while the diagnostics and spatial biology segment's net sales were $81.2 million, representing a decrease of 4% from the second quarter of fiscal 2025.

Bio-Techne's GAAP operating income for the second quarter of fiscal 2026 increased 15% to $54.5 million compared to $47.4 million in the second quarter of fiscal 2025. The GAAP operating margin was 18.4% compared to 16.0% in the second quarter of fiscal 2025.

In terms of non-GAAP results, the adjusted EPS increased to $0.46 per diluted share compared to $0.42 in the same quarter last year. The adjusted operating income increased to $92.0 million in the second quarter of fiscal 2026 compared to $88.7 million in the second quarter of fiscal 2025. The adjusted operating margin was 31.1% for the second quarter of fiscal 2026, compared to 30.1% in the second quarter of fiscal 2025.

Following these announcements, the company's shares moved -1.84%, and are now trading at a price of $68.67. For the full picture, make sure to review BIO-TECHNE Corp's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.